NRIX
Nurix Therapeutics, Inc.
Biotechnology · Healthcare · United States
26.80
close · 2026-10-30
value
57
cheaper than peers57
quality
11
stronger fundamentals11
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 2 years ago | -3.1% | 73 |
| earnings yield, 2 years ago | -9.9% | 64 |
| cash flow yield, 1 year ago | -6.2% | 62 |
| earnings yield, 1 year ago | -10.7% | 57 |
| earnings yield, 3 years ago | -13.8% | 54 |
| price to book | 3.02× | 53 |
| cash flow yield, 3 years ago | -5.9% | 53 |
| earnings yield, latest year | -11.4% | 53 |
| cash flow yield, latest year | -9.0% | 52 |
| price to sales | 79.64× | 15 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 14.4% | 54 |
| return on equity | -80.3% | 30 |
| operating margin | -1041.7% | 20 |
| revenue growth | -79.5% | 8 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | -$164.6M |
| employees | 317 |
| first trade | 2020-07-24 |
| next earnings | 2026-10-12 |
| fundamentals updated | 2026-10-12 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.05 | -2.88 | -2.65 | -3.71 |
| free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M |
| net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M |
| revenue | $84.0M | $54.5M | $77.0M | $38.6M |